APR 10, 2018 10:05 PM PDT

Targeting CDK7 in Treatment-Resistant Cancers

WRITTEN BY: Nouran Amin

Investigators have unveiled a new class of drug that may treat cancer patients who can no longer respond to approved therapeutics. This particular drug may not become available to patients for a long time, however investigators believe if the clinical studies succeed, this drug may be the answer to treatment-resistant cancers.

 

For example, patients diagnosed with breast cancer can become resistant to existing hormone therapeutics, causing their diagnosis to be fatal. This encouraged researchers at the Imperial College of London to develop a drug to combat this cancer-resistance which was in collaboration with Emory University.

 

Lab-based tests that examined the early stages of the proposed drug, ICEC0942, was found to be successful in targeting resistant breast cancers with very few side-effects. ICEC0942 was then licensed to Carrick Therapeutics, which produced the drug into a molecule known as CT7001, later taken to clinical trial.

 

"Treatment-resistant tumors represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do,” says Professor Charles Coombes, from the Department of Surgery & Cancer, "Drugs such as these could help to shift the balance back in favor of the patients, potentially providing a new option to patients for who existing treatments no longer work." Professor Tony Barrett, from the Department of Chemistry, also explains that "This work is the result of extensive collaboration between chemists, biologists and clinicians, which has helped to bring a new treatment from discovery to clinical testing in record time, streamlining the process."

Image via RDmag.com

 

CT7001 works to target an enzyme called CDK7. This enzyme is involved in administrating the lifecycle of cells, this includes cellular proliferation, DNA replication, and division. CDK7 is also part of cellular gene expression in the production of proteins, in other words, CDK7 can affect transcription. In treatment-resistant cancers, such as breast cancer, acute myeloid leukemia, and small-cell lung cancer, the targeting of CDK7 seemed a logical decision for investigators.

 

A wide range of lab tests have successfully shown that ICEC0942 suppresses tumor growth. These test also showed that ICEC0942 was more effective in combination of hormonal therapies. "Drug resistance continues to be a major challenge across many cancer types so it's vital that we explore new ways to tackle tumors that have stopped responding to standard therapies. We hope that this promising new class of drug will offer more options to patients who have few left available to them, and help more people survive their cancer,” says Iain Foukles, Cancer Research UK's executive of research and innovation.

 

Sources: Molecular Cancer Therapeutics, Medical Xpress

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
DEC 13, 2021
Cancer
Mistletoe: Parasite, Symbol of Romance, or Cancer Treatment?
DEC 13, 2021
Mistletoe: Parasite, Symbol of Romance, or Cancer Treatment?
As we approach the winter season, decorative swigs of mistletoe are starting to make their holiday debut.  You may ...
DEC 06, 2021
Microbiology
Sino Biological Launched Omicron Variant Research Reagents
DEC 06, 2021
Sino Biological Launched Omicron Variant Research Reagents
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529) Beijing, China, D ...
DEC 08, 2021
Drug Discovery & Development
Nighttime eating and circadian misalignment leads to glucose intolerance
DEC 08, 2021
Nighttime eating and circadian misalignment leads to glucose intolerance
It might be best to think twice before reaching for that midnight snack. A recent research report published in ...
DEC 16, 2021
Cancer
Age Matters! Young Adults May Need Different Cancer Therapies
DEC 16, 2021
Age Matters! Young Adults May Need Different Cancer Therapies
The incidence of various cancers, including multiple myeloma, colorectal, kidney, and pancreatic cancer, is steadily&nbs ...
DEC 17, 2021
Cannabis Sciences
Δ9-THCP: The Novel Phytocannabinoid with Higher Cannabimimetic Activity than THC
DEC 17, 2021
Δ9-THCP: The Novel Phytocannabinoid with Higher Cannabimimetic Activity than THC
Two novel phytocannabinoids from Cannabis sativa L. have been identified – one with a higher in vivo cannabimimeti ...
JAN 27, 2022
Drug Discovery & Development
The way to the heart is through the toilet seat. Casana raises $30million for its blood pressure monitoring toilet seat.
JAN 27, 2022
The way to the heart is through the toilet seat. Casana raises $30million for its blood pressure monitoring toilet seat.
Casana, a healthcare company based out of Rochester, New York, announced early this week that it has raised $3 ...
Loading Comments...